Abivax’s ulcerative colitis maintenance results showed a high-efficacy signal, but reported cancer cases among recipients pulled the focus away from effectiveness and weighed heavily on sentiment. The company described obefazimod as delivering “landmark” remission outcomes, with placebo-adjusted clinical remission increasing materially versus controls in the Phase 3 maintenance study. Still, investors reacted sharply to safety concerns after malignancies were detected in the high-dose arm, raising immediate questions about risk-benefit framing for continued development and future regulatory conversations. The episode highlights how, in inflammatory disease trials, even relatively infrequent severe events can dominate headlines and coverage ahead of next-stage decision points. Abivax’s disclosure sets up a period of close scrutiny around adjudication details and dose exposure relationships as the company manages downstream communications with regulators and partners.